|
gptkbp:instanceOf
|
gptkb:antiviral_drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:bioavailability
|
~80%
|
|
gptkbp:brand
|
gptkb:Sovaldi
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:prodrug
|
|
gptkbp:chemicalFormula
|
gptkb:nucleotide
|
|
gptkbp:combines
|
gptkb:velpatasvir_and_voxilaprevir
ledipasvir
velpatasvir
|
|
gptkbp:contraindication
|
severe bradycardia with amiodarone
|
|
gptkbp:cost
|
high (notably expensive at launch)
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
gptkb:direct-acting_antiviral
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:interactsWith
|
gptkb:rifampin
gptkb:St._John's_wort
amiodarone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:NS5B_polymerase_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpiryUS
|
2029
|
|
gptkbp:pregnancyCategory
|
B
B1
|
|
gptkbp:proteinBinding
|
61–65%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:synonym
|
gptkb:GS-7977
gptkb:PSI-7977
|
|
gptkbp:usedFor
|
gptkb:hepatitis_C
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sofosbuvir
|